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Purpose: A multicentre open clinical trial was conducted to evaluate the clinical usefulness of a slower titration of topiramate
(TPM) to 300 mg/day as adjunctive therapy for medically intractable partial epilepsies.
Methods: Ninteen centres participated in the trial. Study patients had to have had two or more seizures per 4 weeks whilst taking
maximum tolerated doses of one but not more than two anti-epileptic drugs. The starting dose of TPM was 25 mg/day and the
dose was increased weekly by 25 mg/day until 100 mg/day was reached. Thereafter TPM was increased by 50 mg/day weekly
up to the target dose of 300 mg/day, which was followed by an 8 week maintence phase. Seizure outcomes were measured by
intention-to-treat analysis (ITTA)
Results: Two hundred and thirteen patients entered the study. Median seizure frequency reduction rate was 44.8%, responder
rate was 47.6%, and seizure free rate was 9.0%. These results were comparable to that of TPM 600 mg/day in our previous
controlled trial. In subgroup analysis, seizure free rate was higher in those patients with a lower baseline seizure frequency rate.
Seventeen patients (8.0%) were prematurely withdrawn from the study due to adverse events (AE) or lack of effect. One or
more AEs were reported in 22% of patients, with dizziness being the most frequent AE. Other AEs occurred in less than 5%
of patients.
Conclusion: TPM 300 mg/day was effective and in conjunction with a slower dose-titration, markedly reduced the incidence
of AEs, compared with previous study.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved
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INTRODUCTION
Topiramate (TPM) is a new antiepileptic drug (AED)
having multiple mechanisms of action (Perucca,
1997). Randomized controlled trials of TPM at
variable target doses (200–1000 mg/day) revealed that
TPM 200 mg/day was not significantly more effective
than placebo while TPM in doses of 400 mg/day
or above produced statistically significant seizure
reductions1–6. However there was no evidence of a
dose–response relationship with TPM in the dose
ranges between 400–1000 mg/day, which suggested
that the effective dose of TPM might be between 200
and 400 mg/day7–9. In the pooled analysis of
randomized controlled trials of TPM, most adverse
events (AEs) emerged within the first 8 weeks of
TPM therapy, coinciding with the period of rapid
dose-escalation9, 10. Subsequent studies revealed that
a weekly dose-escalation of TPM of 50 mg/day
was associated with a lower incidence of premature
drug withdrawal than a weekly dose-escalation of
100–200 mg/day without any delay in efficacy11, 12.
The importance of slow dose-titration of TPM
was further stressed by clinical experience obtained
after its marketing approval. Sander13, for instance,
recommended a starting dose of TPM 25 to 50 mg/day
and a gradual dose-escalation by 25 to 50 mg/day
biweekly. However, firm evidence in favour of a
slower dose-escalation has not yet been provided.
We previously conducted a randomized controlled
trial of TPM which adopted a titration schedule of a
weekly increment of 50 mg/day until a target dose
of TPM 600 mg/day14. The efficacy and safety of
TPM in this trial was quite favourable, however,
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no significant differences in efficacy measures were
found between patients taking TPM ≤200 mg/day,
≤400 mg/day, and ≤600 mg/day. The incidence of
AEs was high and the majority of AEs still occurred
during the titration phase. A multicentre open clinical
trial was conducted to evaluate the efficacy of a slower
titration and a target dose of TPM 300 mg/day.
METHODS
Patients
Eligible patients were between 16 and 65 year-old and
a written consent form was signed. Patient inclusion
and exclusion criteria were identical to the previous
controlled trial14 (1999). Briefly, patients had to have
well documented partial onset epilepsies and have two
or more seizures every 4 weeks during the baseline
phase whilst taking maximum tolerated doses of at
least one but not more than two anti-epileptic drugs
(AED). Only clinically identifiable seizures were
counted, which were simple partial motor seizures
(SPMS), complex partial seizures (CPS), and secon-
darily generalized tonic–clonic seizures (SGTCs).
Study Protocols
Nineteen centres participated in the trial after IRB
approval at each centre. The study protocol was
basically similar to our previous controlled trial with
a few exceptions. Patients visited the clinic every
4 week intervals during each 8 weeks of baseline,
titration, and maintenance phases. The dose-titration
consisted of a starting dose of TPM 25 mg/day and
weekly escalation by 25 mg/day until 100 mg/day
was reached. Thereafter TPM was increased weekly
by 50 mg/day until the target dose of 300 mg/day
was obtained. Throughout the study, the doses of
concomitant AEDs were not altered. TPM was
supplied in a pill box and compliance was assessed
by counting tablets remaining in the pill box at
every visit. The physicians assessed adverse events
and seizure frequencies by using seizure diaries,
detailed questions, and examinations at each visits.
Haematologic studies, blood chemistry, urinalysis, and
an electrocardiogram were performed at specified
times throughout the study.
Outcome Measures
Efficacy and safety of TPM were measured by
intention-to-treat analysis (ITTA). The primary
efficacy measure was the change from the baseline
to the experimental period in frequency of seizures
every 4 weeks (median seizure frequency reduction
rate: MSFRR). Secondary efficacy measures were
the responder rate (percentage of patients achieving
>50% seizure frequency reduction: RR), seizure free
rate (SFR), and a global evaluation by patients and
physicians. Subgroup analysis was conducted for
patients entering the maintenance phase. Efficacy
measures (MSFRR, RR, SFR) were analyzed
according to the number of concomitant AEDs,
hepatic enzyme inducing or non-inducing AEDs, daily
dose of TPM at the start of the maintenance phase, and
baseline seizure frequencies.
Statistics
The primary data set for the efficacy analysis
consisted of all study patients for whom at least
one seizure evaluation was available during the
double-blind period. The t-test was used to compare
seizure frequency reduction rates. The responder rates
between two groups were compared by using the
χ2 test. The relationship between baseline seizure
frequencies and SFR was expressed by an odds ratio
(OR) using logistic regression.
RESULTS
Between May and December, 1999, a total of 239
patients were recruited and 213 of them satisfied
the inclusion criteria to enter the titration phase.
One hundred and ninty eight patients entered the
maintenance phase and 182 patients completed the
trial as planned (Fig. 1). The mean dose of TPM at
the end of the titration phase was 264 ± 70 mg/day
and 149 of 199 patients finishing the titration phase
were taking 300 mg/day. The baseline characteristics
of study patients, which are summarized in Table 1,
were comparable with that of the TPM group in
our previous controlled trial except for having a
lower median seizure frequency (3.7 episodes/4
weeks vs. 5.6 episodes/4 weeks, P = 0.03) and a
higher proportion of patients with SPMS (23.9% vs.
12.1%, P = 0.02).
Efficacy
Efficacy data was available for 210 patients (three
patients were withdrawn from the study shortly after
the introduction of TPM). The data is summarized
in Table 2. MSFRR was 44.8%, RR was 47.6% and
SFR was 9.0%, respectively. Slightly more than 50%
of patients and physicians rated TPM as moderately
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Fig. 1: Progression of the trial. Number of patients subjected for ITTA of efficacy n = 210. Number of patients subjected for ITTA of
safety n = 213. Number of patients subjected for the subgroup analysis n = 188.
or markedly effective in this study. In the subgroup
analysis (Table 3), TPM was more effective in SGTC
than CPS in all efficacy measures. However, we
did not find any differences in efficacy between
patients taking one or two AEDs, patients taking
enzyme inducing or non-inducing AEDs, and patients
taking TPM ≤200 mg/day or TPM > 200 mg/day.
For different baseline seizure frequencies, MSFRR
and RR were not significantly different, however,
SFR was significantly higher in patients with lower
baseline seizure frequencies, 31% in patients with
less than 3.7 episodes/4 weeks and 13% in patients
with 3.7 or more episodes/4 weeks (P = 0.003). The
correlations between baseline seizure frequencies and
SFR analyzed by logistic regression analysis revealed
an OR of 0.83 (95% confidence interval: 0.72–0.97),
which suggested that the OR of SFR decreased by 0.83
times in response to an increase in baseline seizure
frequency by one episode/4 wks.
Table 1: Baseline characteristics of study patients.
Variables Current study
(n = 213)
Age (yr-old) 30.1± 10.2 y.o
Sex (M:F) 56.3:43.7
Body weight (kg) 63.6± 11.0
Duration of illness (yrs) 15.8± 9.0
Seizure frequency Median:3.7/4 wks
Mean:8.3± 17.6/4 wks
Seizure types:
SPMS 23.9%
CPS 78.4%
SGTC 44.1%
No. AEDS:
1 drug 24.4%
2 drugs 75.4%
SPMS: simple partial motor seizure; CPS: complex partial seizure;
SGTC: secondarily generalized tonic–clonic seizure.
Safety
Among two hundred and thirteen patients entered the
titration phase, 47 patients (22%) developed AEs.
Thirty eight patients (81%) reported AEs during the
titration phase, 21 patients (45%) reported AEs during
Table 2: Efficacy by ITTA.
Variables Current study
(n = 210)
Median seizure frequency
baseline phase 3.7/4 wks
experimental phase 2.1/4 wks
MSFRR 44.8%
Responder rate 47.6%
Seizure free rate 9.0%
Global evaluation
by physician:
excellent 25.2%
good 27.7%
fair 15.8%
no effect 31.2%
by patients:
excellent 26.2%
good 26.2%
fair 25.2%
no effect 22.3%
MSFRR: median seizure frequency reduction rate.
the maintenance phase: 9 of them (19%) reported the
emergence of AEs only during the maintenance phase.
The most common AE was dizziness (10.0%) which
was followed by somnolence (3.3%), anorexia (2.3%),
weight loss (2.3%), headache (1.9%), abdominal pain
and discomfort (1.9%), nausea and vomiting (1.9%),
visual disturbances (1.4%), and memory impairment
(1.4%). Twenty-nine patients (14%) were prematurely
withdrawn from the study due to AEs in 13 (6.1%),
lack of efficacy in 4 (1.9%) and non-drug related
causes in 12 patients (5.6%). Among those AEs
precipitating premature drug withdrawal, dizziness
was the most common (6 patients), ataxia occurred in
2 patients, and other various AEs in one patient each.
Weight loss
The incidence of weight loss ≥5% and ≥10% of
baseline body weight was 40% and 11% respectively.
The mean weight loss was 1.1± 1.3 kg. We measured
the body mass index [BMI: body weight (kg)÷ height
(m2)] of individual patients and grouped them into the
underweight (BMI < 20), normal (20 ≤ BMI < 25),
and overweight (BMI ≥ 25). The incidence of weight
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Table 3: Subgroup analysis for the efficacy of topiramate (n = 188).
Variables MSFRR P∗ RR P∗ SFR P∗
Seizure types
SPMS (n = 45) 80% 71% 38%
0.001
CPS (n = 138) 60% 56% 25%
0.001 0.008
SGTC (n = 44) 100% 80% 71%
Concomitant AEDS
—1 drug (n = 41) 67% 60% 29%
0.072 0.21 0.19
2 drugs (n = 147) 52% 51% 20%
—E.I-drug (n = 151) 51% 52% 23%
0.07 0.63 0.58
N.E.I - drug (n = 37) 67% 57% 19%
Dose of TPM
≤200 mg/day (n = 50) 50% 50% 24%
0.33 0.60 0.66
>200 mg/day (n = 138) 58% 54% 21%
Baseline Sz. frequency
<3.7/4 wks (n = 90) 47% 48% 31%
0.15 0.20 0.003
>3.7/4 wks (n = 98) 57% 57% 13%
∗ P value calculated by chi-square test; SPMS: simple partial motor seizure; CPS: complex partial seizure; SGTC: secondarily generalized
tonic–clonic seizure; E.I: enzyme inducing; NEI: not enzyme inducing; MSFRR: median seizure frequency reduction rate; RR: responder rate;
SFR: seizure free rate.
loss ≥5% of their baseline body weight was 30% in
the underweight, 37% in the normal body weight, and
50% in the overweight, which was not significantly
different. However, the absolute mean body weight
loss of each group was 0.4 ± 0.8 kg, 0.9 ± 1.1 kg,
and 1.6± 1.6 kg respectively, which was significantly
different (P = 0.0005).
DISCUSSION
Although this study was an open, non-randomized
trial, we adopted a rigid study protocol identical to
our previous controlled trial (except the lower target
dose and slower titration schedule) and recruited a
large number of patients for an indirect comparison of
the outcomes with our previous clinical experiences.
In fact, the baseline characteristics of study patients
and all efficacy measurements of TPM 300 mg/day
in this trial were quite comparable with that of
TPM 600 mg/day in our previous controlled trial
(MSFRR; 44.8% vs. 51.3%, RR; 47.6% vs. 50.6%,
SFR; 9.0% vs. 7.9%, in the current and the previous
study respectively). Also, the RR(47.6%) in this trial
was exactly the same as that of a recent small-
scale placebo-controlled trial which had shown a
significant efficacy of TPM 300 mg/day compared to
placebo15. Therefore, the result seemed to support the
view that TPM 300 mg/day is as effective as higher
doses of TPM, which is consistent with the assump-
tion derived from the meta-analysis of randomized
controlled trials, that the effective dose of TPM is
between 200 mg/day and 400 mg/day7–9. However,
the subgroup analysis based on the concomitant
AEDs (enzyme inducers vs. non-inducers) and the
TPM doses (≤ 200 mg/day vs. >200 mg/day) did
not reveal any significant differences in all efficacy
measures and suggests that TPM 300 mg/day may not
be the minimal effective dose. In fact, the lack of a
dose–response relationship for TPM is consistent with
the results of our previous controlled trial, indicating
that a significant number of patients may respond
to TPM at lower doses than 300 mg/day. Recently,
Stephan et al.16 reported a very wide range of TPM
doses in their responders and one third of their
patients, seizure free for longer than 6 months, were
taking TPM 100 mg/day or less. The discrepancy
between the effective dose of TPM in controlled trials
and clinical experience or subgroup analysis of our
trials might be related to the methodological issues of
efficacy analysis. In previous controlled trials, many
patients did not reach the target dose due to the
fixed and rapid titration schedules of TPM, yet the
analysis was conducted according to the TPM dosage
that patients were assigned. Reife et al.9 recently
conducted an analysis of pooled data from controlled
trials of TPM according to the dosage at which patients
completed the study instead of the target doses. Their
results showed a much greater efficacy of TPM at
200 mg/day than placebo and there was evidence of
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slightly better efficacies as TPM doses got higher.
Their work strongly suggests that the concept of
a specific or minimal effective dose of TPM is a
statistical issue rather than a clinical issue. Therefore,
the demonstration of comparable efficacies between
TPM 300 mg/day and TPM 600 mg/day should be
interpreted as that most patients respond to TPM
300 mg/day or less. The slightly higher numbers of
efficacy measures and better global evaluation by the
patients and the physicians in our previous controlled
trial suggested that some patients might respond better
to higher doses of TPM than 300 mg/day.
In the subgroup analysis, SGTC was found to be
better responsive to TPM than CPS, which was some-
what different from the result of our previous study as
well as the results of meta-analysis. The reason for the
discrepancy is unclear and further investigation may
be needed. However, TPM is a broad spectrum AED
and has been found quite effective against refractory
GTC17. The other variable affecting the outcome
measure was the baseline seizure frequency; MSFRR
and RR were not different but SFR was significantly
higher in patients whose baseline seizure frequencies
were less than 3.7 episodes/4 week compared to
the patients with higher baseline seizure frequencies.
Logistic regression analysis also revealed an inverse
correlation between baseline seizure frequencies and
SFR, which was consistent with the general concept
that successful seizure control is largely dependent
upon the severity of seizures18. This may suggest that
a significant proportion of patients with intractable
partial epilepsies having less frequent seizures can be
successfully controlled by add-on of TPM, this may
significantly improve their quality of life.
The adoption of a slower dose-titration schedule in
this trial markedly decreased the incidence of AEs
which was only 22% compared to 81.3% in our
previous placebo controlled trial. This number was
even lower than the incidence of AEs in the placebo
group of our previous trial, which might be related
to the open nature of the study. The most common
AE was dizziness, a non-specific CNS symptom, and
the incidence of other AEs were less than 5%. The
incidence of anorexia and abdominal pain/discomfort,
the most common and troublesome AEs in our
previous controlled study, were only 2.3% and 1.9%
respectively. These results suggest that anorexia and
G–I symptoms as with other AEs are subjected
to the process of physiological adaptation. On the
other hand, the incidence of TPM-related premature
withdrawel from the study was not different from
our previous study, which might suggest the presence
of a ceiling effect in the TPM-related premature
withdrawel rate.
The incidence of weight loss (≥5% of baseline
body weight) by TPM add-on therapy was 40% which
was comparable with our previous controlled trial,
however, the mean weight loss was only 1.1 ± 1.3 kg
compared to 3.4 ± 4.9 kg in our previous trial and
only 2.3% of patients reported weight loss as an AE
compared to 8.8% in our previous study. This might
be related to both a slower dose-titration and a lower
target dose of TPM.
In conclusion, this study demonstrated that TPM
300 mg/day was effective and, in conjunction with a
slower dose-titration, greatly reduced the incidence of
AEs. However the subgroup analysis did not support
that TPM 300 mg/day was the minimal effective dose.
Baseline seizure frequencies were closely related with
SFR but not MSFRR or RR, which need to be
considered in future clinical trials.
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